Table 3.
Clinical characteristics of clinically confirmed Parkinson cases and those whose diagnosis was not confirmed
| Clinical characteristics | Clinically examined | |
|---|---|---|
| PD Confirmed | PD not confirmed | |
| Number of participants | 76 | 57 |
| Age at examination, years (mean±SD) | 71.9±7.3 | 72.9±6.8 |
| Diagnosis hospital, N (%) | ||
| Municipal level | 63 (82.9) | 27 (47.4) |
| District level | 12 (15.8) | 19 (33.3) |
| Missing | 1 (1.3) | 11 (19.3) |
| Specialty of clinics, (%) | ||
| PD specialty clinics | 28 (36.8) | 5 (8.8) |
| Neurology | 46 (60.5) | 34 (59.6) |
| Others | 1 (1.3) | 7 (12.3) |
| Missing | 1 (1.3) | 11 (19.3) |
| Age at diagnosis, years (mean±SD) | 63.5 ± 8.0 | 63.4 ± 9.5 |
| Age at first symptoms, years (mean±SD) | 62.1 ± 8.5 | 60.6 ± 10.7 |
| Duration at enrollment, years (mean±SD) | 8.4 ± 4.4 | 9.3 ± 6.7 |
| Bradykinesia*, (%) | 72/73 (98.6) | 18/48 (37.5) |
| Rest tremor*, (%) | 66/73 (90.4) | 40/53 (75.5) |
| Muscle rigidity*, (%) | 62/73 (84.9) | 13/47 (27.7) |
| Postural instability*, (%) | 39/65 (60.0) | 9/44 (20.5) |
| Asymmetric onset*, (%) | 72/74 (97.3) | 40/54 (74.1) |
| Ever treated by*, (%) | ||
| Levodopa | 72/75 (96.0) | 32/52 (61.5) |
| Dopamine agonist | 20/74 (27.0) | 0/54 (0) |
| Amantadine | 36 (47.4) | 7/56 (12.5) |
| Other medications for PD | 37/74 (50.0) | 13/56 (23.2) |
| Response to dopaminergic therapy*, (%) | 70/70 (100) | 7/22 (31.8) |
*
Denominators are provided when there are missing observations.